Botulinum Toxin Injection for Retrograde Cricopharyngeal Dysfunction: A Prospective Cohort Study
The Laryngoscope · 2024
DOI: 10.1002/lary.31591 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Laryngoscope, 2024. Verfasst von Can Doruk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Voice and Swallowing, Department of Otolaryngology-Head & Neck Surgery, Columbia University Irving Medical Center, New York, New York, U.S…. Hauptthemen laut MEDLINE: Deglutition Disorders. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Retrograde Cricopharyngeal Dysfunction (RCPD) is treated by botulinum toxin (BTX) injection into the cricopharyngeus. This prospective study compares the effectiveness and side effects of operating room (OR) and in‐office (IO) injections.
Methods
Patients over 18 years of age with inability to burp, abdominal, thoracic, or cervical gurgling sounds, bloating, and excessive flatulence were diagnosed with RCPD and included in the study. Injections were performed in the OR (80U) or IO (30U) by the senior author. An RCPD questionnaire quantifying major and minor symptoms on a Likert scale, Eating Assessment Tool‐10 (EAT‐10), and Generalized Anxiety Score−7 (GAD‐7), were completed preinjection; at 1, 2, and 3 weeks; and 3 months postoperatively. Linear mixed models were used to analyze effects of BTX injection on RCPD symptoms, the EAT‐10, and the GAD‐7.
Results
108 (55 M/53F) patients completed the pretreatment survey, 53 (31 OR vs. 22 IO) completed the 3‐week follow‐up, and 36 (22 OR vs. 14 IO) completed the 3‐month questionnaire. Average posttreatment RCPD scores were significantly lower in both groups at 3 weeks and 3 months ( p < 0.0001), There was no difference between IO or OR ( p = 0.4924). GAD‐7 scores were significantly lower in both groups at week 3 ( p = 0.0018) and month 3 ( p = 0.0012). Postinjection EAT‐10 scores were significantly higher in OR compared with IO ( p = 0.0379).
Conclusion
OR and IO injections are equally effective in the treatment of RCPD. Postinjection dysphagia is more severe after the OR injections which may be related to higher doses of BTX used. General anxiety levels decrease with treatment. Level of Evidence 2 Laryngoscope , 134:4614–4619, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Voice and Swallowing, Department of Otolaryngology-Head & Neck Surgery, Columbia University Irving Medical Center, New York, New York, U.S.A.
- Department of Otolaryngology-Head & Neck Surgery, Istanbul Demiroglu Bilim University, Istanbul, Turkey.
- Department of Otolaryngology-Head & Neck Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida, U.S.A.
ORCID-Profile: Can Doruk, Evan L Kennedy, Courtney Tipton, Michael J Pitman
Zitieren
APA
Doruk, C., Kennedy, E. L., Tipton, C., Abdel-Aty, Y., & Pitman, M. J. (2024). Botulinum Toxin Injection for Retrograde Cricopharyngeal Dysfunction: A Prospective Cohort Study. The Laryngoscope. https://doi.org/10.1002/lary.31591
Vancouver
Doruk C, Kennedy EL, Tipton C, Abdel-Aty Y, Pitman MJ. Botulinum Toxin Injection for Retrograde Cricopharyngeal Dysfunction: A Prospective Cohort Study. The Laryngoscope. 2024. doi:10.1002/lary.31591
BibTeX
@article{Doruk2024,
author = {Doruk, Can and Kennedy, Evan L and Tipton, Courtney and Abdel-Aty, Yassmeen and Pitman, Michael J},
title = {Botulinum Toxin Injection for Retrograde Cricopharyngeal Dysfunction: A Prospective Cohort Study},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31591}
}
EUVIMED